Vernon Hills, IL November 17, 2008 - Applied NeuroSolutions, Inc. (OTC BB:APNS, www.appliedneurosolutions.com), a Company focused on the development of an integrated product portfolio for the treatment and diagnosis of Alzheimer’s disease (AD), today announced the appointment of Gary C. Parks, a finance and  pharmaceutical industry executive to its Board of Directors replacing Robert S. Vaters, who resigned due to an increase in his external business commitments.

Since 1993 Mr. Parks has served as the Secretary, Treasurer and Chief Financial Officer of Immtech Pharmaceuticals, Inc., (AMEX: IMM) a company dedicated to the discovery and development of therapies to treat infectious diseases that affect the global community.  In addition to oversight of all domestic and international financial operations serving the US, Africa, South America, China and Asia, Mr. Parks also shares the investor relations function for Immtech.

Previously, Mr. Parks held financial operations roles of increasing responsibility including Vice President, Finance at Smallbone, Inc., from 1989 until 1993, Division Controller with International Paper from 1986 to 1989 and Vice President of Serck Baker, Inc., a subsidiary of BTR plc, from 1982 to 1989 and board member of Serck Baker de Venezuela.

Ellen R. Hoffing, APNS Chairman commented, “As a long standing and active CFO of a publicly traded healthcare company, Gary Parks adds very contemporary knowledge in financial and investment management, strategy, mergers, acquisitions and shareholder relations which are valuable skill sets to support APNS’s successful transition from R&D to commercialization of our Alzheimer’s disease-focused  pipeline. I feel fortunate that Gary Parks has joined our Board, and expect he will be an active and knowledgeable resource and advisor.  On behalf of management and the Board, I want to wish Robert Vaters well and thank him for his service.”

About Applied NeuroSolutions:

Applied NeuroSolutions, Inc. (OTC BB:APNS - News) is developing diagnostics and therapeutics to detect and treat Alzheimer's disease (AD) building on discoveries originating from the Albert Einstein College of Medicine.  Applied NeuroSolutions is in a collaboration with Eli Lilly and Company to develop novel therapeutic compounds to treat the progression of AD.  For its diagnostic pipeline, Applied NeuroSolutions is focused on both cerebrospinal fluid (CSF) and serum tests to detect AD at a very early stage.  The P-Tau 231 test now being offered for use in clinical trials can effectively differentiate AD patients from those with other neurological diseases that have similar symptoms. There is currently no FDA approved diagnostic test to detect AD. Alzheimer's disease currently afflicts over five million Americans, and the world market for AD therapy is currently estimated to be 30 million patients.  For more information, visit www.AppliedNeuroSolutions.com

This press release contains forward-looking statements about Applied NeuroSolutions. The company wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at www.AppliedNeuroSolutions.com, and review the company's filings with the Securities and Exchange Commission.

Contact:
Applied NeuroSolutions 847-573-8000
Ellen Hoffing, President, CEO
David Ellison, CFO